|Bid||21.29 x 1100|
|Ask||21.31 x 4000|
|Day's Range||20.82 - 22.04|
|52 Week Range||17.76 - 40.14|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.89|
LEXINGTON, Mass., September 22, 2021--Dicerna today announced new executive leadership appointments.
LEXINGTON, Mass., September 02, 2021--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 16th Annual Citi Biopharma Conference on Sept. 9, 2021 at 7:55 a.m. ET.
The stock market’s behavior might appear baffling at times, but when you see shares of a biotech sinking, the reason is almost always one of two ready-made options: regulatory rejection or disappointing clinical trial results. For disappointed investors of Dicerna Pharmaceuticals (DRNA), the latter case sent the stock tumbling by 28% in a single session last week. Specifically, the downturn came about after the company released data from the phase 2 trial evaluating nedosiran as a treatment for